RxDoctor Payments Data

Megan Callahan, MD

Neurology · Attleboro, MANPI 1780642611

Payments from drug & device makers

$25,050in general payments, 2019–2025

Across 1,226 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • SK Life Science, Inc.$2K
  • Biogen$1K
  • Novartis$1K
  • Pfizer$1K
  • Lundbeck LLC$1K
  • plus $17K from 54 others

What the payments were for

  • Speaking & faculty fees$580%
  • Food & beverage$24,77899%
  • Education$2141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)99$1,852
SK Life Science, Inc.68$1,743
Biogen72$1,359
Novartis65$1,112
Pfizer45$1,092
Lundbeck LLC42$1,059
EMD Serono, Inc.40$1,054
Merz Pharmaceuticals, LLC34$986
UCB, Inc.41$943
Lilly USA, LLC46$908
Neurelis, Inc.36$863
AstraZeneca30$749
Bristol Myers Squibb45$709
Eisai Inc.30$647
Amneal Pharmaceuticals LLC33$626
Neurocrine Biosciences, Inc.33$623
Johnson & Johnson34$604
Sanofi32$592
MDD US Operations, LLC25$527
Amgen(2 entities)30$527
Teva Pharmaceuticals USA, Inc.32$525
Sunovion Pharmaceuticals Inc.45$502
CSL Behring19$464
Biohaven Pharmaceutical Holding Company Ltd.15$373
Genentech USA, Inc.17$335
Acadia Pharmaceuticals Inc16$304
Grifols USA, LLC19$295
Mallinckrodt Hospital Products Inc.13$284
Livanova USA, Inc.7$248
Vanda Pharmaceuticals Inc.11$242
Kyowa Kirin, Inc.11$227
Supernus Pharmaceuticals, Inc.18$211
Sumitomo Pharma America, Inc.9$179
ANI Pharmaceuticals, Inc.7$172
Argenx US, Inc.7$167
Xeris Pharmaceuticals, Inc.8$145
Acorda Therapeutics, Inc7$140
Otsuka America Pharmaceutical, Inc.7$136
Biohaven Pharmaceuticals, Inc.7$135
Ipsen Biopharmaceuticals, Inc6$135
E.r. Squibb & Sons, L.L.C.4$121
Adamas Pharmaceuticals, Inc.5$102
Upsher-smith Laboratories LLC4$101
Banner Life Sciences, LLC3$101
GE HealthCare12$93
Inspire Medical Systems, Inc.5$90
Impel Pharmaceuticals Inc.4$72
Merz North America, Inc.4$68
Microtransponder, Inc.1$65
Sanofi-aventis U.S. LLC3$60
Neuropace, Inc.3$59
Bardy Diagnostics, Inc.3$59
Catalyst Pharmaceuticals, Inc.1$54
Life Molecular Imaging Ltd3$41
Avion Pharmaceuticals2$37
Avanir Pharmaceuticals, Inc.2$32
Medtronic(2 entities)2$30
Genentech, Inc.1$24
Arbor Pharmaceuticals, Inc.1$18
Jazz Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,050 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$120,437
Medicare patients
380
Services billed
863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4624$359,503
CopaxoneGlatiramer Acetate12$84,180
NuplazidPimavanserin Tartrate15$67,501
Aimovig AutoinjectorErenumab-Aooe28$39,240
Nurtec OdtRimegepant Sulfate22$36,857
FycompaPerampanel26$32,636
AptiomEslicarbazepine Acetate23$29,037
LamictalLamotrigine12$22,297
Emgality PenGalcanezumab-Gnlm28$19,779
Dalfampridine ErDalfampridine17$10,076
Memantine Hcl141$9,364
NeuproRotigotine11$8,904
Carbamazepine ErCarbamazepine44$7,965
Rivastigmine54$7,424
Lacosamide40$4,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$525$84,18012 claims
Acadia Pharmaceuticals IncNuplazid$304$67,50115 claims
PfizerNurtec Odt, Dilantin$1,092$41,33535 claims
Eisai Inc.Fycompa$647$32,63626 claims
Sunovion Pharmaceuticals Inc.Aptiom$502$29,03723 claims
UCB, Inc.Neupro$943$8,90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 761 neurology providers in Massachusetts.

Other neurology in Attleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →